Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
20 nov. 2024 16h30 HE
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for...
Ultragenyx Presents Positive Update on GTX-102 Angelman Syndrome Program at FAST’s 17th Annual Global Science Summit
09 nov. 2024 10h30 HE
|
Ultragenyx Pharmaceutical Inc.
Phase 1/2 data show improvements across all domains and confirm that Phase 3 Aspire study is amply powered to establish efficacy of GTX-102 Phase 3 program on track to begin enrollment by...
Ultragenyx Reports Third Quarter 2024 Financial Results and Corporate Update
05 nov. 2024 16h01 HE
|
Ultragenyx Pharmaceutical Inc.
Third quarter 2024 total revenue grew 42% versus prior year to $139 million, including Crysvita® revenue of $98 million and Dojolvi® revenue of $21 million Reaffirmed 2024 expected total revenue...
Ultragenyx to Host Conference Call for Third Quarter 2024 Financial Results and Corporate Update
29 oct. 2024 16h05 HE
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for...
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
18 oct. 2024 16h30 HE
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for...
Ultragenyx Receives Breakthrough Therapy Designation for Setrusumab (UX143) in Osteogenesis Imperfecta
07 oct. 2024 08h00 HE
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare...
Ultragenyx Provides Update on Stage 1 Cohorts in Pivotal Phase 1/2/3 Cyprus2+ Study Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease
03 oct. 2024 16h30 HE
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today reported that the Phase 1/2/3 Cyprus2+ study of its UX701 gene therapy has demonstrated...
Ultragenyx Announces Upcoming Setrusumab (UX143) Presentations at the ASBMR 2024 Annual Meeting
26 sept. 2024 08h00 HE
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that it will present seven abstracts related to its ongoing late-stage program...
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
18 sept. 2024 17h00 HE
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for...
Ultragenyx presenta Evkeeza® (concentrado de evinacumab para solución para infusión) en España para el tratamiento de la hipercolesterolemia familiar homocigótica (HFho)
03 sept. 2024 02h30 HE
|
Ultragenyx Pharmaceutical Inc.
MADRID, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), una empresa biofarmacéutica centrada en el desarrollo y la comercialización de nuevos tratamientos para...